References
Original articles
van der Heijden, M. S. et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2309863 (2023)
McGregor, B. A. et al. The Double Antibody Drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann. Oncol. https://doi.org/10.1016/j.annonc.2023.09.3114 (2023)
Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2308795 (2023)
Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2304753 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. From the ESMO Congress 2023. Nat Rev Clin Oncol 21, 3 (2024). https://doi.org/10.1038/s41571-023-00835-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00835-1
- Springer Nature Limited